Acumen Pharmaceuticals, Inc. 8-K

What Happened Acumen Pharmaceuticals, Inc. (ABOS) filed an 8-K reporting the results of its annual meeting of stockholders held on June 3, 2026. Of 72,227,580 shares outstanding as of the record date, 57,051,456 shares (approximately 78.99%) were present or represented by proxy. Stockholders elected three Class II directors to serve until the 2029 annual meeting, ratified Ernst & Young LLP as the independent auditor for 2026, and approved the Company’s Amended and Restated 2021 Equity Incentive Plan.

Key Details

• Director elections (terms through 2029):
  • George Golumbeski, Ph.D.: 37,305,711 votes For; 68,820 Withheld; 19,676,925 broker non-votes.
  • Derrell Porter, M.D.: 30,926,494 votes For; 6,448,037 Withheld; 19,676,925 broker non-votes.
  • Laura Stoppel, Ph.D.: 30,812,559 votes For; 6,561,972 Withheld; 19,676,925 broker non-votes.
• Auditor ratification: Ernst & Young LLP ratified with 56,934,900 For, 113,074 Against, and 3,482 Abstentions.
• Equity plan approval: Amended and Restated 2021 Equity Incentive Plan approved with 30,731,776 For, 6,618,621 Against, 24,134 Abstentions, and 19,676,925 broker non-votes.

Why It Matters These votes finalize governance and compensation-related matters that affect corporate oversight and the company’s ability to grant equity awards. The election of the three directors determines board composition through 2029; ratification of Ernst & Young confirms the company’s independent auditor for 2026; and approval of the amended equity plan authorizes issuance of equity awards under that plan, which can affect future share-based compensation and potential dilution.